Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9697076 | 0.99 | TSHR (0.47) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| SCHEMBL9696959 | 0.94 | TSHR (0.47) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| Hydrochloric Acid SCHEMBL9697582 | 0.93 | TSHR (0.46) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| Hydrochloric Acid SCHEMBL9753453 | 0.91 | TSHR (0.46) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| SCHEMBL9697916 | 0.88 | NOD2 (0.42) | TSHRSMN1; SMN2NOD2NOD1MAPT | |
| Hydrochloric Acid SCHEMBL9697011 | 0.87 | NOD2 (0.42) | TSHRSMN1; SMN2NOD2NOD1MAPT | |
| SCHEMBL9753017 | 0.86 | TSHR (0.45) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| SCHEMBL9695958 | 0.84 | TSHR (0.60) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| SCHEMBL9695933 | 0.83 | TSHR (0.48) | TSHRSMN1; SMN2USP2NOD2NOD1 | |
| SCHEMBL9696030 | 0.82 | TNKS (0.42) | SMN1; SMN2USP2NOD2NOD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | claimed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20100015228-A1 | CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-5149700-A | Antiarrhythmic agent | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| WO-1991018904-A1 | SUBSTITUTED ARYLSULFONAMIDES AND BENZAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | TSHR 1014/4885SMN1; SMN2 1823/4885USP2 4206/4885 |
| US-20100015228-A1 | CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | TRPV1, ATP2A1, TRPM2 | TSHR 1758/4885SMN1; SMN2 2760/4885USP2 2967/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | TSHR 1118/4885SMN1; SMN2 1844/4885USP2 4122/4885 |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | TSHR 4155/4885SMN1; SMN2 640/4885USP2 2714/4885 |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | TSHR 1014/4885SMN1; SMN2 1823/4885USP2 4206/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | TSHR 1118/4885SMN1; SMN2 1844/4885USP2 4122/4885 |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | TSHR 1014/4885SMN1; SMN2 1823/4885USP2 4206/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | TSHR 2491/4885SMN1; SMN2 4521/4885USP2 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.